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Introduction {#sec004}
============

Leprosy is a chronic human disease caused by the yet-uncultured pathogen *Mycobacterium leprae* \[[@pntd.0007946.ref001]\]. Although curable with multidrug therapy (MDT), leprosy remains a public health problem in South America, Africa, South and Southeast Asia, and Micronesia, where over 200,000 new leprosy cases are reported each year \[[@pntd.0007946.ref001]\]. The incidence rate has remained steady since 2005 \[[@pntd.0007946.ref002]\], and global statistics of childhood cases show that transmission of leprosy continues to some extent in more than 100 countries \[[@pntd.0007946.ref003]\]. Therefore, surveillance is needed to ensure that chemotherapy of leprosy remains effective for the foreseeable future \[[@pntd.0007946.ref004]\].

*M*. *leprae* is susceptible to a wide range of antibiotics; diamino-diphenylsulfone (DDS; also known as dapsone) monotherapy was used to treat leprosy from 1940 to 1981, and multidrug therapy (MDT) was then implemented worldwide based on recommendations by the WHO (1982--2000). The components of MDT, comprising rifampicin, dapsone, and clofazimine, and several second-line drugs, ofloxacin, minocycline, and clarithromycin, are sometimes employed as therapeutic agents \[[@pntd.0007946.ref001]\]. Resistance to antileprosy drugs in *M*. *leprae* has been observed in several leprosy-endemic regions by the Global Sentinel Surveillance for Drug Resistance in Leprosy program coordinated by the WHO \[[@pntd.0007946.ref005]\]. The emergence of drug-resistant (DR) and multidrug-resistant (MDR) *M*. *leprae* has also been increasingly reported in other areas \[[@pntd.0007946.ref002], [@pntd.0007946.ref006]--[@pntd.0007946.ref012]\].

The presence of mutations in drug resistance-determining regions (DRDRs) of the rpoB, folP1, and gyrA genes is associated with rifampicin, dapsone, and quinolone resistance, respectively. Testing methods include *M*. *leprae* DRDR primers and a polymerase chain reaction (PCR) sequencing method recommended by the WHO \[[@pntd.0007946.ref013]\], GenoType LepraeDR \[[@pntd.0007946.ref014]\], and qPCR-high-resolution melt analysis \[[@pntd.0007946.ref015]\], among others. However, the use of nested PCR and the TaqMan SNP Genotyping Assay for this type of testing has not been reported. Nested PCR is necessary for studies on certain human tissue microbiota because it can amplify the target DNA with concentrations several-fold lower than those of standard PCR \[[@pntd.0007946.ref016]\]. As new SNP mutations associated with antibiotic resistance have been detected by *M*. *leprae* whole-genome sequencing \[[@pntd.0007946.ref001]\], the TaqMan SNP Genotyping Assay is a potential molecular method for detecting drug resistance in *M*. *leprae*.

Leprosy is still endemic in 61 counties in the Yunnan, Sichuan, and Guizhou Provinces of China (prevalence ≥ 1/100,000). Indeed, more than half of the country's new cases (336/634) in 2017 were detected in these three provinces, making it the area with the highest leprosy burden in China. In the present study, skin biopsy, formalin-fixed, paraffin-embedded (FFPE), and skin-slit smear (SSS) samples of new and relapsed cases from multibacillary (MB) and paucibacillary (PB) patients with leprosy were used. Our aim was to develop an easily accessed and highly sensitive nested polymerase chain reaction (nested PCR) and Custom TaqMan SNP Genotyping Assay that easily detects drug resistance in leprosy.

Methods {#sec005}
=======

Ethics statement {#sec006}
----------------

This study was approved by the Medical Ethics Committee of Beijing Friendship Hospital, Capital Medical University, Beijing, P. R. China. Written informed consent was obtained from all study participants or from their parents or guardians. All of the procedures in the study, including biological sample collection and testing involving human participants, were performed in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.

Human specimens {#sec007}
---------------

This molecular epidemiology study was performed with Chinese patients with leprosy from 2003 to 2011. Seventy-six patients were included, mainly from Yunnan Province, including the Center for Disease Control and Prevention (CDC) of Wenshan Zhuang and Miao Autonomous Prefecture (WS), Honghe Hani and Yi Autonomous Prefecture (HH), and Kunming (KM) (the capital of Yunnan) and Guizhou, Sichuan, Hunan, and Shandong Provinces; Tianjin; and Tibet. In this study, all patients diagnosed with leprosy by clinicians using defined criteria, SSSs and biopsies were appropriately treated with DDS and/or MDT according to WHO guidelines. Seventy-six clinical specimens were obtained from the patients with leprosy for routine diagnosis of leprosy in China. These specimens were divided into two groups according to disease status: new cases (n = 50) and relapsed cases (n = 26). The specimens were divided by type into skin biopsy (n = 37), FFPE (n = 38) and SSS (n = 1) groups. The specimens were also divided based on the bacterial index (BI) value into high BI (BI≥2; n = 57) and low BI (BI\<2; n = 16) groups. BI information was not available for three patients.

DNA extraction and quality control {#sec008}
----------------------------------

Genomic DNA was extracted from FFPE and skin biopsy specimens using the Qiagen DNeasy^™^ Blood and Tissue Kit (Qiagen, Beijing, China) according to the manufacturer's instructions. Briefly, paraffin was removed from the FFPE specimens by vortexing and 10 min of incubation with 1.2 mL xylene, followed by two washes with pure (200 proof) ethanol. The FFPE and skin biopsy specimens were then incubated with 20 μL proteinase K and 180 μL ATL lysis buffer overnight in a heat block at 56°C. The lysed emulsion was further purified with DNeasy Spin-Column Kit. The DNA was eluted in 100 μl of AE elution buffer provided in the kit; 1 to 2 μl of DNA was typically sufficient for one PCR.

For DNA yield, the total amount of DNA for clinical samples was assessed using [spectrophotometry](https://www.sciencedirect.com/topics/medicine-and-dentistry/spectrophotometry) (Malcom e-spect, Tokyo, Japan) and a Qubit 4.0 fluorometer with Qubit dsDNA HS Assay Kit (Life Technologies, Massachusetts, Waltham, USA) according to the manufacturer's protocols. The total amount of DNA was obtained in ng/μl.

Simple PCR, nested PCR, and sequencing {#sec009}
--------------------------------------

The primers used for simple PCR were recommended by the WHO (see [Table 1](#pntd.0007946.t001){ref-type="table"}). The 20-μl reaction mixture contained 1 μl of primer mix (250 nM of each primer for folP1, rpoB, and gyrA), 10 μl of 2X PCR Mixture (Cat No: MFKIT02 for folP1, MFKIT03 for rpoB, and MFKIT04 for gyrA, Beijing Jinsheng Lida Technology Trade Co., Ltd., Beijing, China), and 2--50 ng of DNA template (1 μl). Reactions were carried out using a Peltier thermal cycler (BIO-RAD, California, USA), and the thermal cycling conditions were as follows: 2 min at 95 °C, followed by 35 cycles of 15 sec at 95 °C, 15 sec at 58 °C and 60 sec at 72 °C, and a final extension step of 7 min at 72 °C.

10.1371/journal.pntd.0007946.t001

###### Primers for simple PCR/sequencing and nested PCR/sequencing for drug susceptibility testing in *M*. *leprae* used in this study.

![](pntd.0007946.t001){#pntd.0007946.t001g}

  --------------------------------------------------------------------------------------------------------------------------------------------------
  Target gene   Primers                          Nucleotide sequences (5\'-3\')   Product length                                PCR type
  ------------- -------------------------------- -------------------------------- --------------------------------------------- --------------------
  folP1         Forward                          5\'-CTGACAATTCGTTCTCAGATGG-3\'   394 bp[\*](#t001fn001){ref-type="table-fn"}   Nested PCR (outer)

  Reverse       5\'-TAATTCGGAGCCTCATA-3\'                                                                                       

  Forward       5\'-CTTGATCCTGACGATGCT G-3\'     255 bp                           Simple PCR/Nested PCR (inner)\                
                                                                                  /Sequencing                                   

  Reverse       5\'-CCCACCAGATCGTTGACG-3\'                                                                                      

  rpoB          Forward                          5\'-GTCGGTATGTCGCGGATGGA-3\'     581 bp                                        Nested PCR (outer)

  Reverse       5\'-CGTGGCGAGACATCCATGTAAT-3\'                                                                                  

  Forward       5\'-GTCGGTATGTCGCGGATGGA-3\'     279 bp                           Simple PCR/Nested PCR (inner)\                
                                                                                  /Sequencing                                   

  Reverse       5\'-CGACAATGAACCGATCAGACC-3\'                                                                                   

  gyrA          Forward                          5\'-TATACAGCGGGTTGAGCGG-3\'      358 bp                                        Nested PCR (outer)

  Reverse       5\'-GATGGTCTCAAACCGGTACATC-3\'                                                                                  

  Forward       5\'-ACAATAACGCATCGCTGCCG-3\'     225 bp                           Simple PCR/Nested PCR (inner)\                
                                                                                  /Sequencing                                   

  Reverse       5\'-ACCCGGCGAACCGAAATT G-3\'                                                                                    
  --------------------------------------------------------------------------------------------------------------------------------------------------

\*Bp = base pair; PCR = polymerase chain reaction; nested PCR = single-tube nested PCR.

Simple PCR/STNPCR (inner) primers of folP1, rpoB, and gyrA recommended by the WHO;

STNPCR (outer) primers designed by authors through Primer Express 5.0.

The simple PCR primers recommended by the WHO were used as the inner primers for the nested PCR, and the outer primers of the nested PCR primer were designed using Primer Express 5.0 ([Table 1](#pntd.0007946.t001){ref-type="table"}). The first round of nested PCR was performed as following. The 20-μl reaction mixture for nested PCR contained 10 μl of 2× PCR Mixture, 1 μl of outer primer mix (250 nM), Cat No: MFKIT02 for folP1, MFKIT03 for rpoB, and MFKIT04 for gyrA (Beijing Jinsheng Lida Technology Trade Co., Ltd., Beijing, China) and 2--50 ng of DNA template (1 μl). The thermal cycling conditions were as follows: 7 min at 94 °C, followed by 40 cycles of 30 sec at 94 °C, 30 sec at 58 °C and 60 sec at 72 °C, and a final extension step of 7 min at 72 °C. Products were visualized on a 1.5% agarose gel containing GeneFinder (Zeesan Biotech, Xiamen, Fujian, China). The second round of nested PCR was performed as the procedure of simple PCR.

The nucleotide sequences of both strands of the relevant segment of the folP1, rpoB, and gyrA genes were determined by direct sequencing of the PCR product using an ABI 3730 Automated DNA Sequencer (Sangon Biotech Co., Ltd). The primers used for sequencing are listed in [Table 1](#pntd.0007946.t001){ref-type="table"}. Sequence data were analyzed using the nucleotide database in Basic Local Alignment Search Tool (BLAST) (<http://blast.ncbi.nlm.nih.gov>) to identify mutations associated with drug resistance.

TaqMan SNP genotyping {#sec010}
---------------------

Genotyping of folP1 drug resistance loci ACC53GCC, CCC55CTC, CCC55CGC, and ACC53ATC was performed using TaqMan SNP Genotyping Master Mix (Applied Biosystems, Foster City, CA, USA) and the ABI 7500 fast real-time polymerase chain reaction (PCR) system (Applied Biosystems). The final reaction volume for PCR was 10 μl, which contained 1 μl of 10 ng/μl genomic DNA or 1^st^ PCR products, 5 μl of TaqMan Universal PCR Master Mix, 0.25 μl of 200 nM VIC/FAM-labeled probe, and 3.75 μl double-distilled water. The probes were designed by Beacon Designer 8.00, synthesized as Custom TaqMan SNP Genotyping Assays, Nonhuman (Applied Biosystems). The probe sequences are indicated in [Table 2](#pntd.0007946.t002){ref-type="table"}. PCR amplification was carried out in 96-well plates containing unknown genotype samples, wildtype samples (e.g., 55CCC), heterozygous samples (e.g., 55CCC/CGC), and homozygous samples (e.g., 55CGC) as positive controls and no-template controls. Thermal cycle conditions were as follows: 1 cycle of 60 °C for 1 min, 95 °C for 10 min, 40 cycles of 95 °C for 15 sec and 60 °C for 1 min, and 1 cycle of 60 °C for 1 min. Reactions were analyzed using Allelic Discrimination Sequence Detection Software from Applied Biosystems.

10.1371/journal.pntd.0007946.t002

###### Primers and probes of Custom TaqMan SNP genotyping assays for the folP1 loci for drug susceptibility testing in *M*. *leprae*.
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  --------------------------- ------------------------- -------------------
  folP1 ACC53GCC              Forward Primer            GGCGCGGCGATTGTC
  Reverse Primer              ACTCGAGGATCGGTCCTAATGG    
  Probe 1 Wild type \[VIC\]   CCGGGTCGATTCG             
  Probe 2 Mutant \[FAM\]      CGGGCCGATTCG              
  folP1 CCC55CTC              Forward Primer            CGTCGGTGGCGAATCGA
  Reverse Primer              TCAACTCGAGGATCGGTCCTAA    
  Probe 1 Wild type \[VIC\]   TGGCACCGGGCCGG            
  Probe 2 Mutant \[FAM\]      TGGCACCGAGCCGG            
  folP1 CCC55CGC              Forward Primer            ACGTCGGTGGCGAATCG
  Reverse Primer              CAACTCGAGGATCGGTCCTAATG   
  Probe 1 Wild type \[VIC\]   ACCCGGCCCGGTGC            
  Probe 2 Mutant \[FAM\]      CCGGCGCGGTGC              
  folP1 ACC53ATC              Forward Primer            GGCGCGGCGATTGTC
  Reverse Primer              ACTCGAGGATCGGTCCTAATGG    
  Probe 1 Wild type \[VIC\]   CGAATCGACCCGGCCC          
  Probe 2 Mutant \[FAM\]      CGAATCGATCCGGCCC          
  --------------------------- ------------------------- -------------------

bp = base pair; PCR = polymerase chain reaction; STNPCR = single-tube nested PCR.

Statistical analysis {#sec011}
--------------------

The DNA concentration from different sample types was compared using GraphPad Prism software version 5.0 (GraphPad Software Inc., San Diego, CA, USA). Following Tukey's honest significant difference (HSD) test was used for analysis of the average DNA quantification values obtained from skin biopsy or FFPE samples by [spectrophotometry](https://www.sciencedirect.com/topics/medicine-and-dentistry/spectrophotometry) and Qubit dsDNA HS Assay. Comparisons of the three molecular assays for drug resistance were performed by Statistical Package for the Social Sciences (SPSS) version 16.0. Concordance between the results was determined by kappa values (κ), and p values were calculated. Significant differences between assays were determined by McNemar's test, and p values were calculated.

Results {#sec012}
=======

Basic characteristics of leprosy patients {#sec013}
-----------------------------------------

Seventy-six leprosy cases from different regions were included. The basic information for each study group is summarized in [Table 3](#pntd.0007946.t003){ref-type="table"}.

10.1371/journal.pntd.0007946.t003

###### Clinical characteristics of the leprosy patients enrolled in this study.
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  -----------------------------------------------------------------------------------------------------
  Variables                                                                               Cases (%)
  ------------------------------------------- ------------------------------------------- -------------
  WHO\                                        MB[\*](#t003fn001){ref-type="table-fn"}     70 (92.10%)
  Classification                                                                          

  PB[\*](#t003fn001){ref-type="table-fn"}     6 (7.89%)                                   

  Ridley-Jopling\                             LL[\*\*](#t003fn002){ref-type="table-fn"}   26 (34.21%)
  Classification                                                                          

  BL[\*\*](#t003fn002){ref-type="table-fn"}   34 (44.73%)                                 

  BB[\*\*](#t003fn002){ref-type="table-fn"}   4 (5.26%)                                   

  BT[\*\*](#t003fn002){ref-type="table-fn"}   9 (11.84%)                                  

  TT[\*\*](#t003fn002){ref-type="table-fn"}   3 (3.95%)                                   

  Sex                                         Female                                      17 (22.37%)

  Male                                        59 (77.63%)                                 

  Age (years)                                 ≤20                                         7 (9.21%)

  21--39                                      30 (39.47%)                                 

  40--59                                      28 (36.84%)                                 

  ≥60                                         11 (14.47%)                                 

  Province                                    Yunnan                                      54 (71.05%)

  Guizhou                                     7 (9.21%)                                   

  Sichuan                                     5 (6.57%)                                   

  Hunan                                       4 (5.26%)                                   

  Hubei                                       1 (1.32%)                                   

  Fujian                                      1 (1.32%)                                   

  Shandong                                    1 (1.32%)                                   

  Tianjin                                     1 (1.32%)                                   

  Jiangsu                                     1 (1.32%)                                   

  Tibet                                       1 (1.32%)                                   

  Disease Status                              New                                         50 (65.79%)

  Relapsed                                    26 (34.21%)                                 

  Specimen Type                               Skin biopsy                                 37 (48.68%)

  FFPE                                        38 (50.00%)                                 

  SSS                                         1 (1.32%)                                   

  BI                                          ≥2                                          58 (76.32%)

  \<2                                         18 (23.68%)                                 
  -----------------------------------------------------------------------------------------------------

\*MB: multibacillary, PB: paucibacillary.

\*\*TT: tuberculoid tuberculoid, BT: borderline tuberculoid, BB: mid-borderline, BL: borderline lepromatous, LL: lepromatous lepromatous

Comparison of DNA yield between skin biopsy and FFPE samples {#sec014}
------------------------------------------------------------

The DNA concentrations from different sample types were compared by [spectrophotometry](https://www.sciencedirect.com/topics/medicine-and-dentistry/spectrophotometry) and Qubit dsDNA HS Assay. FFPE samples generated a slightly higher DNA yield than did skin biopsy samples, but this difference was not significant ([Fig 1](#pntd.0007946.g001){ref-type="fig"}, [S2 Table](#pntd.0007946.s002){ref-type="supplementary-material"}). The DNA concentration of skin biopsy samples measured by the Qubit dsDNA HS Assay method (average = 53.01 ng/μl, SD = 46.53) was slightly lower than that obtained by [spectrophotometry](https://www.sciencedirect.com/topics/medicine-and-dentistry/spectrophotometry) (average = 65.24 ng/μl, SD = 55.42). In contrast, the DNA concentration of FFPE samples measured by the Qubit dsDNA HS Assay method (average = 107.9 ng/μl, SD = 72.99) was considerably lower than that obtained by [spectrophotometry](https://www.sciencedirect.com/topics/medicine-and-dentistry/spectrophotometry) (average = 58.73 ng/μl, SD = 42.54) ([Fig 1](#pntd.0007946.g001){ref-type="fig"}, [S2 Table](#pntd.0007946.s002){ref-type="supplementary-material"}).

![DNA concentrations (ng/μl) resulting from *M*. *leprae* clinic specimens.](pntd.0007946.g001){#pntd.0007946.g001}

Analytical specificity of simple PCR, nested PCR and TaqMan methods {#sec015}
-------------------------------------------------------------------

The specificity of the primers/probes was tested by carrying out amplification with purified genomic DNA from fifteen different mycobacterial species and four nonmycobacterial species. Regarding the gyrA and folP1 genes, all primer/probe sets produced amplicons when DNA isolated from *M*. *lepraemurium* was used as the template, but no amplicons were observed when DNA from other species of *Mycobacterium* or nonmycobacterial species was used (see [Table 4](#pntd.0007946.t004){ref-type="table"}). For rpoB, *M*. *bovis* BCG-Pasteur, *M*. *bovis* \[AFZ/ZZ/97\], *M*. *bovis* \[Ravenel\], *M*. *kansasii*, and *M*. *ulcerans* amplicons were present, as verified by BLAST (<https://blast.ncbi.nlm.nih.gov/Blast.cgi>), and the sequencing results were consistent with *Mycobacterium* species detected.

10.1371/journal.pntd.0007946.t004

###### Specificity of nested PCR, and TaqMan SNP genotyping assay for drug resistance testing of *Mycobacterium leprae*.
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  Species                                                           rpoB                                                                                                gyrA   folP1                  
  ----------------------------------------------------------------- --------------------------------------------------------------------------------------------------- ------ ------- ---- ---- ---- ----
  *Mycobacterial species*                                           *from CSU*[\*](#t004fn001){ref-type="table-fn"} *and NHDP*[\*\*](#t004fn002){ref-type="table-fn"}                                 
  *M*. *lepraemurium*[^\#^](#t004fn003){ref-type="table-fn"}        \+                                                                                                  \+     \+      \+   \+   \+   \+
  *M*. *avium*                                                      \-                                                                                                  \-     \-      \-   \-   \-   \-
  *M*. *bovis BCG-Pasteur*[\#](#t004fn003){ref-type="table-fn"}     \-                                                                                                  \+     \-      \-   \-   \-   \-
  *M*. *bovis \[AFZ/ZZ/97\]*[\#](#t004fn003){ref-type="table-fn"}   \-                                                                                                  \+     \-      \-   \-   \-   \-
  *M*. *bovis \[Ravenel\]*[\#](#t004fn003){ref-type="table-fn"}     \-                                                                                                  \+     \-      \-   \-   \-   \-
  *M*. *flavescens*                                                 \-                                                                                                  \-     \-      \-   \-   \-   \-
  *M*. *intracellulare*                                             \-                                                                                                  \-     \-      \-   \-   \-   \-
  *M*. *kansasii*                                                   \-                                                                                                  \+     \-      \-   \-   \-   \-
  *M*. *marinum*                                                    \-                                                                                                  \-     \-      \-   \-   \-   \-
  *M*. *phlei*                                                      \-                                                                                                  \-     \-      \-   \-   \-   \-
  *M*. *smegmatis*                                                  \-                                                                                                  \-     \-      \-   \-   \-   \-
  *M*. *simiae*                                                     \-                                                                                                  \-     \-      \-   \-   \-   \-
  *M*. *ulcerans*                                                   \-                                                                                                  \+     \-      \-   \-   \-   \-
  *Nonmycobacterial species*                                        *from NHDP*[\*\*](#t004fn002){ref-type="table-fn"}                                                                                
  *Streptococcus pyogenes*                                          \-                                                                                                  \-     \-      \-   \-   \-   \-
  *Clostridium perfringens*                                         \-                                                                                                  \-     \-      \-   \-   \-   \-
  *Escherichia coli*                                                \-                                                                                                  \-     \-      \-   \-   \-   \-
  *Staphylococcus epidermidis*                                      \-                                                                                                  \-     \-      \-   \-   \-   \-

\*CSU = Colorado State University, Fort Collins, Colorado

\*\*NHDP = National Hansen's Disease Program

^\#^: The results of PCR/sequencing and nested PCR/sequencing were consistent with the *Mycobacterium* species detected.

Performance of drug resistance testing of clinical samples {#sec016}
----------------------------------------------------------

PCR to amplify folP1, gyrA and rpoB DRDRs was performed on all samples. PCR amplicons corresponding to DRDRs in the folP1, gyrA and rpoB genes were investigated by direct sequencing of the PCR amplicons obtained using a modification of the WHO guidelines for the Global Surveillance of Drug Resistance in Leprosy \[[@pntd.0007946.ref013]\]. Positive PCR results and informative sequences were obtained for folP1 in 15/76 (19.73%) and 3/76 (5.26%) cases, for rpoB in 44/76 (57.89%) and 39/76 (51.35%) cases and for gyrA in 61/76 (80.26%) and 57/76 (75.00%) cases, respectively.

Due to initial PCR inhibition, we developed a nested PCR of DRDRs for the three genes. The positive ratio of nested PCR and sequences increased to 66/76 (86.84%) and 64/76 (84.21%) for folP1, 63/76 (82.89%) and 60/76 (78.94%) for rpoB, and 65/76 (85.52%) and 61/76 (80.26%) for gyrA. We developed a TaqMan SNP assay for the four DRDR loci in the folP1 gene. Because the amplification efficiency of genomic DNA was too low to perform the TaqMan SNP assay, we used the first cycle of the PCR product of nested PCR as the template. The rate for the TaqMan SNP Assay positivity of the folP1 gene was 60/76 (78.94%) for CCC55CTC, CCC55CGC, and ACC53ATC loci and 66/76 (86.84%) for the ACC53GCC locus ([Table 5](#pntd.0007946.t005){ref-type="table"}).

10.1371/journal.pntd.0007946.t005

###### Results of DNA sequencing and TaqMan SNP genotyping in the folP1, rpoB and gyrA genes of *Mycobacterium leprae* in DRDRs.
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  Specimens   RpoB, n (%)   GyrA, n (%)   folP1, n (%)   folP1, TaqMan[\*\*](#t005fn002){ref-type="table-fn"}, n (%)                                                                                                            
  ----------- ------------- ------------- -------------- ------------------------------------------------------------- -------- --------- -------- -------- -------- -------- -------- -------- -------- -------- -------- ---- ----
  Total       76            44            39             63                                                            60       61        57       65       61       15       4        66       64       60       60       60   66
  57.89%      51.35%        82.89%        78.94%         80.26%                                                        75.00%   85.52%    80.26%   19.73%   5.26%    86.84%   84.21%   78.94%   78.94%   78.94%   86.84%        
  New         48            27            24             40                                                            39       35        33       38       36       10       1        40       39       36       37       39   41
  56.25%      50.00%        83.33%        81.25%         72.91%                                                        68.75%   79.16%    75.00%   20.83%   2.08%    83.33%   81.25%   75.00%   77.08%   81.25%   85.41%        
  Relapsed    28            17            15             24                                                            21       26        24       26       25       5        3        24       23       24       23       21   25
  60.71%      53.57%        85.71%        75.00%         92.85%                                                        85.71%   92.85%    89.28%   17.85%   10.71%   85.71%   82.14%   85.71%   82.14%   75.00%   89.28%        
  Biopsy      64            35            32             54                                                            51       50        48       53       51       12       4        56       55       51       50       52   56
  54.68%      50.00%        84.37%        79.68%         78.12%                                                        75.00%   82.81%    79.68%   18.75%   6%       87.50%   85.93%   79.68%   78.12%   81.25%   87.50%        
  FFPE        11            8             6              8                                                             8        10        8        11       9        3        0        9        9        8        9        7    9
  72.72%      54.54%        72.72%        72.72%         90.90%                                                        72.72%   100.00%   81.81%   27.27%   0.00%    81.81%   81.81%   72.72%   81.81%   63.63%   81.81%        
  SSS         1             1             1              1                                                             1        1         1        1        1        0        0        1        1        1        1        1    1
  100%        100%          100%          100%           100%                                                          100%     100%      100%     0%       0%       100%     100%     100%     100%     100%     100%          
  BI (≥2)     58            37            34             48                                                            47       47        44       48       47       15       4        51       49       47       48       46   51
  63.79%      58.62%        66.74%        81.03%         81.03%                                                        75.86%   82.75%    81.03%   25.86%   6.89%    87.93%   84.48%   81.03%   87.25%   79.31%   87.93%        
  BI (\<2)    18            6             5              9                                                             13       14        13       16       15       0        0        15       15       13       12       14   15
  33.33%      27.78%        50.00%        72.22%         77.78%                                                        72.22%   88.89%    83.33%   0.00%    0.00%    83.33%   83.33%   72.22%   66.67%   77.78%   83.33%        
  MB          70            44            39             60                                                            57       57        54       61       57       15       4        62       60       55       58       56   62
  62.85%      51.42%        85.71%        81.42%         81.42%                                                        77.14%   87.14%    81.42%   21.42%   5.71%    88.57%   85.71%   78.57%   82.85%   80.00%   88.57%        
  PB          6             0             0              3                                                             3        4         3        4        4        0        0        4        4        5        2        4    4
  0.00%       0.00%         50.00%        50.00%         66.67%                                                        50.00%   66.67%    66.67%   0.00%    0.00%    66.67%   66.67%   83.33%   33.33%   66.67%   66.67%        

\*Seq: sequencing;

\*\*TaqMan: TaqMan SNP genotyping.

Comparison of the three molecular assays for drug resistance based on kappa and McNemar's tests {#sec017}
-----------------------------------------------------------------------------------------------

The kappa test was used to analyze the concordance of the results collected from the three molecular assays. Concordance was observed between PCR/sequencing and nested PCR/sequencing of rpoB and gyrA and between nested PCR/sequencing and TaqMan SNP Assay of folP1 (ACC53GCC), with index values of 0.439, 0.849 and 0.257, respectively (p values of 0.000, 0.000, and 0.024, respectively) ([Table 6](#pntd.0007946.t006){ref-type="table"}). This finding indicates that the two tests showed high consistency for the detection of drug resistance in leprosy patients.

10.1371/journal.pntd.0007946.t006

###### Comparison of the results of three molecular assays of drug resistance using clinical samples of leprosy patients.

![](pntd.0007946.t006){#pntd.0007946.t006g}

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Methods                         Gene (loci)        Kappa test                                   McNemar's test                               
  ------------------------------- ------------------ -------------------------------------------- -------------------------------------------- --------------------------------------------
  PCR/Seq *vs* nested PCR/Seq     rpoB               0.439                                        0.000[\*](#t006fn001){ref-type="table-fn"}   0.000[\*](#t006fn001){ref-type="table-fn"}

  gyrA                            0.849              0.000[\*](#t006fn001){ref-type="table-fn"}   0.125                                        

  folP1                           0.021              0.374                                        0.000[\*](#t006fn001){ref-type="table-fn"}   

  PCR/Seq *vs* TaqMan SNP Assay   folP1 (ACC53GCC)   0.029                                        0.289                                        0.000[\*](#t006fn001){ref-type="table-fn"}

  folP1 (ACC53ATC)                0.029              0.289                                        0.000[\*](#t006fn001){ref-type="table-fn"}   

  folP1 (CCC55CGC)                0.029              0.289                                        0.000[\*](#t006fn001){ref-type="table-fn"}   

  folP1 (CCC55CGC)                0.021              0.374                                        0.000[\*](#t006fn001){ref-type="table-fn"}   

  Nested PCR/Seq *vs*\            folP1 (ACC53GCC)   0.257                                        0.024[\*](#t006fn001){ref-type="table-fn"}   0.791
  TaqMan SNP Assay                                                                                                                             

  folP1 (ACC53ATC)                0.128              0.205                                        0.503                                        

  folP1 (CCC55CGC)                0.041              0.715                                        0.523                                        

  folP1 (CCC55CTC)                -0.049             0.667                                        0.541                                        
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

\*p\<0.05, significant difference.

McNemar's test showed that the sensitivity of nested PCR/sequencing of rpoB and folP1 was significantly positively correlated with the results of PCR/sequencing of rpoB and folP1 (p \< 0.05). McNemar's test also showed that the sensitivity of the TaqMan SNP assay was significantly positively correlated with the PCR/sequencing results, suggesting that the nested PCR/seq and TaqMan SNP assays were helpful for detecting drug resistance in *M*. *leprae* ([Table 6](#pntd.0007946.t006){ref-type="table"}).

In addition, we compared the results regarding mutations in specimens detected by the TaqMan SNP Assay and by nested PCR/sequencing, and the two results were identical.

Characteristics of patients with mutated strains {#sec018}
------------------------------------------------

Data on the mutations observed in the folP1, gyrA, and rpoB genes are summarized in [Table 7](#pntd.0007946.t007){ref-type="table"}. Mutations were found in folP1 and gyrA in nineteen patients.

10.1371/journal.pntd.0007946.t007

###### folP, gyrA, and rpoB gene mutations related to drug resistance in isolates from leprosy patients in China.

![](pntd.0007946.t007){#pntd.0007946.t007g}

  ------------------------------------------------------------------------------------------------------------------------------------------------------------
  Case\                                               Mutation (position) of folP1   gyrA                                                           
  no.                                                                                                                                               
  ----------- ---- --- --------- --------- ---------- ------------------------------ ---------------- ----------- ---------------- ---------------- ----------
  f1-3        69   M   Hunan     MDT       New                                                                                     CCC55CTC         

  f1-4        55   M   Hunan     MDT       New                                                                                     CCC55CTC         

  F1-5        31   F   Yunnan    MDT       New                                                                                     CCC55CTC         

  f1-6        22   F   Yunnan    MDT       New        ACC53GCC                                                                                      

  f1-7        60   M   Yunnan    MDT       Relapsed                                                                                CCC55CTC         

  f1-8        32   F   Yunnan    MDT       New        ACC53\[G/A\]CC                                                               CCC55C\[T/C\]C   

  f1-9        55   M   Yunnan    MDT       New                                                                    CCC55C\[G/C\]C                    

  f1-10       32   M   Yunnan    MDT       New                                                                                     CCC55C\[T/C\]C   

  F1-12       45   M   Yunnan    MDT       New                                                                                     CCC55CTC         

  f1-21       40   M   Yunnan    DDS/MDT   Relapsed   ACC53GCC                                                                                      

  f-1-2       33   M   Jiangsu   MDT       Relapsed   ACC53GCC                                                                                      

  f-1-10      50   M   Yunnan    MDT       New                                                                    CCC55CGC                          

  f-1-21      50   M   Sichuan   DDS/MDT   Relapsed                                                               CCC55CGC                          

  f-1-22      43   M   Sichuan   MDT       New                                                                    CCC55C\[G/C\]C                    

  F-1-24      68   M   Sichuan   MDT       Relapsed                                                                                CCC55CTC         

  f-1-26      32   M   Yunnan    MDT       New                                                                    CCC55CGC                          GCA91GTA

  f = 1--1    38   F   Yunnan    MDT       Relapsed                                                               CCC55C\[G/C\]C                    

  f = 1--9    34   M   Yunnan    MDT       Relapsed                                  ACC53A\          CGG54\      CCC55C\[G/C\]C                    
                                                                                     \[C/T\]\[C/T\]   \[C/G\]GG                                     

  f = 1--27   37   M   Yunnan    MDT       New                                       ACC53ATC                                                       
  ------------------------------------------------------------------------------------------------------------------------------------------------------------

Regarding the detection of dapsone resistance, nineteen isolates showed mutations in the folP1 gene, and these mutations were classified into five patterns. Four isolates showed an A to G mutation resulting in a Thr to Ala at amino acid 53 (ACC-GCC). The ratio of mutant homozygous to mutant heterozygous genotypes was 2 to 2. One isolate showed a C to T mutation resulting in a Thr to Ile at amino acid 53 (ACC-ATC) without a mutant heterozygous genotype. One isolate showed a C to T mutation resulting in a Thr to Ile at amino acid 53 (ACC-A\[C/T\]\[C/T\]) with a mutant heterozygous genotype. Seven isolates showed a C to G mutation resulting in a Thr to Ile at amino acid 55 (CCC-CGC). The ratio of mutant homozygous to mutant heterozygous genotypes was 4 to 3. Eight isolates showed a C to T mutation resulting in a Thr to Ile at amino acid 55 (CCC-CTC). The ratio of mutant homozygous to mutant heterozygous genotypes was 6 to 2. In addition, we found a C to G mutation resulting in a Arg to Gly at amino acid 54 (CGG-\[C/G\]GG), which was reported previously by Nakata et al. \[[@pntd.0007946.ref017]\] ([Table 7](#pntd.0007946.t007){ref-type="table"}). The chromatogram for the drug susceptibility and resistance loci in the folP1 gene of *M*. *leprae* detected by Sanger sequencing is shown in [Fig 2](#pntd.0007946.g002){ref-type="fig"}. The drug susceptibility and resistance loci in the folP1 gene of *M*. *leprae* detected by the Custom TaqMan SNP assay are shown in Figs [3](#pntd.0007946.g003){ref-type="fig"} and [4](#pntd.0007946.g004){ref-type="fig"}.

![Sanger sequencing chromatograms indicated drug resistance loci in the folP1 Gene of *M*. *leprae*.\
(A) 53ACC and 55CCC; (B) 53GCC; (C) 53ATC; (D) 55CTC; (E) 55CGC; (F) 53\[A/G\]CC and 55C\[C/T\]C; and \[G\] ACC53A\[C/T\]\[C/T\], CGG54\[C/G\]GG and CCC55C\[C/G\]C in the folP1 gene. (A) Wildtype homozygous; (B-E) mutant homozygous; (F-G) mutant heterozygous.](pntd.0007946.g002){#pntd.0007946.g002}

![Multicomponent plot figures indicated drug resistance loci (CCC55CGC) in the folP1 Gene of *M*. *leprae*.\
The DNA samples were genotyped using the Custom TaqMan SNP Genotyping Assay System. Major (also wildtype) alleles were detected by 2\'-chloro-7\'-phenyl-1,4-dichloro-6-carboxyfluorescein (VIC)-labeled probes (green) and minor alleles by 6-carboxyfluorescein (FAM)-labeled probes (blue). (A) Mutant homozygous G/G. (B) Mutant heterozygous C/G. (C) Wildtype homozygous C/C; (D) Allele discrimination plot showing alleles as wildtype homozygous C/C (lower right cluster), mutant heterozygous C/G (middle cluster), and mutant homozygous G/G (upper left) for the CCC55CGC loci of folP1 gene by Custom TaqMan SNP Genotyping Assay using 7500 Software v2.3, Applied Biosystem, USA. SNP indicates a single-nucleotide polymorphism.](pntd.0007946.g003){#pntd.0007946.g003}

![An allele discrimination plot indicated drug resistance loci in the folP1 Gene of *M*. *leprae*.\
(A) ACC53GCC, (B) ACC53ATC, (C) CCC55CGC, and (D) CCC55CTC. Red, green, and blue dots represent homozygous genotypes, heterozygous genotypes and mutant homozygous genotypes, respectively, and the cross on the bottom left of the plot indicates the no-template control or failed PCR.](pntd.0007946.g004){#pntd.0007946.g004}

Regarding ofloxacin resistance, one isolate showed mutations in the GyrA gene of *M*. *leprae*. The isolates showed a C to T mutation resulting in a Ala to Val at amino acid 91 (GCA-GTA) ([Table 7](#pntd.0007946.t007){ref-type="table"}).

No isolates showed mutations in *M*. *leprae* rpoB gene DRDRs. One isolate exhibited multidrug resistance and carried mutations in the folP1 and gyrA genes, resulting in resistance to dapsone and ofloxacin.

The mutation ratio of new and relapsed leprosy patients is shown in [Table 7](#pntd.0007946.t007){ref-type="table"}. The rates of mutations detected in folP1, gyrA, folP1/gyrA and rpoB were 25.00% (19/76), 1.31% (1/76), 1.31% (1/76), and 0.00% (0/76), respectively.

The drug resistance mutations of *M*. *leprae* in new and relapsed patients with leprosy are shown in [Table 8](#pntd.0007946.t008){ref-type="table"}.

10.1371/journal.pntd.0007946.t008

###### The mutation rates of new and relapsed leprosy patients.

![](pntd.0007946.t008){#pntd.0007946.t008g}

  Mutation                                  Total   New       Relapsed                  
  ----------------------------------------- ------- --------- ---------- --------- ---- ---------
  No mutation                               57      75.00%    38         76.00%    19   73.08%
  Dapsone (folP1)                           19      25.00%    12         24.00%    7    26.92%
  Quinolones (gyrA)                         1       1.31%     1          2.00%     0    0.00%
  Dapsone and quinolones (folP1 and gyrA)   1       1.31%     1          2.00%     0    0.00%
  RFP (rpoB)                                0       0.00%     0          0.00%     0    0.00%
  Total                                     76      100.00%   50         100.00%   26   100.00%

Discussion {#sec019}
==========

In this study, we investigated drug-resistance mutations in new and relapsed cases of leprosy in Southwest China and developed two molecular biological methods, involving nested PCR/sequencing and the TaqMan SNP Genotyping Assay, for MB and PB leprosy patients.

Regarding specificity, this study assessed whether the simple PCR/sequencing, nested PCR/sequencing and TaqMan SNP genotyping methods involved in the testing of *M*. *leprae* drug resistance are capable of detecting other *Mycobacterium* species or nonmycobacterial species. The *Mycobacterium* species expressing the rpoB, gyrA, and folP1 genes retrieved by NCBI/gene are shown in [S2 Table](#pntd.0007946.s002){ref-type="supplementary-material"}. In this study, no cross-detection was found for any primers/probes used for gyrA or for folP1. Positive rpoB amplicons can be distinguished as the appropriate *Mycobacterium* species using NCBI/BLAST. As the rpoB gene is also expressed in other mycobacterial species, theoretically, the method can also be performed to detect the rpoB gene in the other four *Mycobacterium* species. The results suggested no risk of interference from mycobacterial species that might be encountered when testing *M*. *leprae* for drug resistance.

Point mutations at codon 53 or 55 of the *M*. *leprae* folP1 gene have been confirmed to result in dapsone resistance \[[@pntd.0007946.ref018]\]. folP1 mutation rates among relapsed cases have been reported to be 26% (5/19) in the Philippines (Cebu), 8.3% (2/24) in Myanmar (Yangon), 10% (1/10) in Indonesia (North Maluku and North Sulawesi) \[[@pntd.0007946.ref010]\], 57% (8/14) in Vietnam (the central and highland regions) \[[@pntd.0007946.ref017]\], and 9.1% (2/22) in Japan \[[@pntd.0007946.ref019]\]. In this study, the frequencies of dapsone resistance in new and relapsed cases were 24.00% (12/50) and 26.92% (7/26), respectively. In this study, the rate of mutation of the folP1 gene in relapsed cases (26.92%, 7/26) was slightly higher than that in newly detected cases (24.00%, 12/50). These results are different from those of a previous study in Shandong, China \[[@pntd.0007946.ref020]\], which reported frequencies of dapsone resistance in new and relapsed cases of 1.6% (1/61) and 0% (0/6), respectively. In addition, a previous study in Shandong, China, reported that the mutation rate of the rpoB gene in 52 new cases was 9.6% (5/52), though rpoB mutation was not found in new or relapsed cases in this study. These different drug resistance characteristics may be due to differences in demographics from Southwest China to North China and the small sample size of this study.

Based on the result of an antimicrobial resistance study on leprosy by the WHO surveillance network, skin biopsy specimens from MB leprosy cases at sentinel sites of 19 countries from the period 2009--2015 were included, and resistance to rifampicin, dapsone and ofloxacin according to PCR sequencing of rpoB, folP1 and gyrA gene DRDRs was studied \[[@pntd.0007946.ref021]\]. The PCR/sequencing method has been widely applied in MB leprosy patients; however, drug resistance among PB leprosy patients and the use of FFPE specimens have seldom been discussed \[[@pntd.0007946.ref015]\]. In this study, we developed a nested PCR and TaqMan SNP Genotyping Assay, which were used for drug resistance testing in MB and PB patients. The performance of the two methods was also assessed to detect drug resistance within DRDRs of *M*. *leprae* using DNA obtained from skin biopsy as well as from partially degraded FFPE specimens.

The three molecular methods were applied to 73 specimens with BI values ranging from 0 (no bacilli visible) to 6 (\>1000 bacilli per microscopic field), thereby enabling a comparison of the efficiency of the methods between the BI≥2 and BI \<2 groups ([Table 4](#pntd.0007946.t004){ref-type="table"}). As expected, there was a direct correlation between PCR/sequencing positivity and the BI, but surprisingly, nested PCR/seq and the TaqMan SNP Genotyping Assay increased the sensitivity dramatically, and successful detection of drug resistance was achieved with some specimens with a BI as low as 0. In addition, distinguishing heterozygous genotypes and mutant homozygous genotypes from homozygous genotypes based on an allele discrimination plot of the TaqMan SNP Genotyping Assay was easily accomplished.

Dapsone monotherapy is usually regarded as the reason for drug resistance in relapsed cases. However, only two relapsed cases with folP1 mutation had previously undergone DDS monotherapy. Of notable concern was the detection of the folP1 mutation related to drug resistance in five patients undergoing MDT who had not previously undergone DDS treatment. This may be due to irregular medication use as a result of self-treatment. Despite the known presence of dapsone resistance mutations, relapsed patients are commonly retreated with an MDT regimen that contains dapsone in Colombia \[[@pntd.0007946.ref022]\] and China.

Our study has some limitations. It was a retrospective study with a small sample size. Thus, a prospective study with a standardized sampling method should be performed. The TaqMan SNP Genotyping Assay can detect only one SNP locus each time, and more effective detection systems, such as the TaqMan array card (TAC), should be developed. We focused on mutations only within DRDRs. Future studies should focus on additional SNPs related to drug resistance in *M*. *leprae* as well as transmission markers of leprosy.

Conclusion {#sec020}
----------

Overall, our findings highlight a new molecular approach involving nested PCR, and the TaqMan SNP Genotyping Assay offers a rapid and highly sensitive tool for testing resistance in *M*. *leprae*. In addition, the TaqMan SNP Genotyping Assay easily distinguishes heterozygous genotypes and mutant homozygous genotypes from homozygous genotypes.

Using these tools, more information on drug resistance can be obtained from skin biopsy, FFPE, and SSS specimens from leprosy patients. However, the TaqMan SNP Genotyping Assay developed in the study can only detect one SNP mutant locus at a time. Thus, new gene detection systems, such as the TAC, integrating more SNP loci of drug resistance genes into an effective assay, should be developed. Finally, additional genetic mutations related to first-line and second-line drug resistance should be considered for incorporation into future gene detection systems.

Supporting information {#sec021}
======================

###### DNA concentrations (ng/μl) obtained for *Mycobacterium* species and *M*. *leprae* clinical specimens, as determined using [spectrophotometry](https://www.sciencedirect.com/topics/medicine-and-dentistry/spectrophotometry) and Qubit dsDNA HS assay.
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Click here for additional data file.

###### *Mycobacterium* species expression of the rpoB, gyrA, and folP1 genes, as reported by NCBI/gene.
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Click here for additional data file.
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